Gary Remington, MD, PhD
Professor
gary.remington@camh.ca
Gary Remington researches the pharmacotherapy of schizophrenia, particularly as it applies to psychosis and treatment response. He is currently part of a working group at the University of Toronto focusing on the different symptom domains and subtypes of schizophrenia, using a combination of preclinical and clinical investigations including animal models, neuroimaging (PET, MRI, fMRI), neuropsychology, electrophysiology, virtual reality, and human clinical trials. Dr. Remington holds the position of Chief, Schizophrenia Program at the Centre for Addiction and Mental Health.